Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company focused on innovative genetic therapies, has announced plans for an underwritten public offering of its common stock. The company will sell all shares in this proposed offering, with TD Cowen and BMO Capital Markets serving as joint book-running managers. Additionally, Prime Medicine intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The offering's completion is subject to market conditions and other factors, with final terms to be disclosed in a forthcoming prospectus supplement filed with the U.S. Securities and Exchange Commission $(SEC.UK)$.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.